GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Abrhale, Tesfom ^a,b   Brodie, Angela ^c   Sabnis, Gauri ^c   Macedo, Luciana ^c   Tian, Changsheng ^a   Yue, Binbin ^a   Serrero, Ginette ^a,c  

^a A&G Pharmaceutical   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN RECEPTOR; LETROZOLE; PROGRANULIN; PROTEIN BCL 2; TRANSFER RNA; AROMATASE INHIBITOR; GRN PROTEIN, HUMAN; NITRILE; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TRIAZOLE DERIVATIVE;

AGAR MEDIUM; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UPREGULATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NITRILES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; TRIAZOLES;

EID: 79958029744     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-231     Document Type: Article

References (43)

1. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005, 26:331-45. 10.1210/er.2004-0015, 15814851.
2. Grodin JM, Siiteri PK, McDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973, 36:207-14. 10.1210/jcem-36-2-207, 4688315.
3. Burak WE, Quinn AL, Farrar WB, Brueggemeier RW. Androgens influence estrogen-induced responses in human breast carcinoma cells through cytochrome P450 aromatase. Breast Cancer Res Treat 1997, 44:57-64. 10.1023/A:1005782311558, 9164678.
4. Chen S, Zhou D, Okubo T, Kao YC, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999, 6:149-56. 10.1677/erc.0.0060149, 10731103.
5. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23:7979-89. 10.1038/sj.onc.1208076, 15489915.
6. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007, 72:7-25. 10.1016/j.steroids.2006.10.009, 2566956, 17169390.
7. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005, 65:5380-9. 10.1158/0008-5472.CAN-04-4502, 15958587.
8. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance?. J Steroid Biochem Mol Biol 2006, 102:232-40. 10.1016/j.jsbmb.2006.09.012, 1829446, 17055257.
9. Dowsett M, Martin LA, Smith I, Johnston S. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005, 95:167-172. 10.1016/j.jsbmb.2005.04.022, 15982868.
10. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000, 82:501-13. 2363333, 10682656.
11. Nicholson RI, Hutcheson IR, Britton D, Knowlden JM, Jones HE, Harper ME, Hiscox SE, Barrow D, Gee JM. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 2005, 93:257-62. 10.1016/j.jsbmb.2004.12.006, 15860268.
12. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JM. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004, 10:346S-54S. 10.1158/1078-0432.CCR-031206, 14734490.
13. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10:2435-46.
14. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 1996, 38:57-66. 10.1007/BF01803784, 8825123.
15. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R. Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 1996, 56:3350-8.
16. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142:2776-88. 10.1210/en.142.7.2776, 11415996.
17. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003, 144:1032-44. 10.1210/en.2002-220620, 12586780.
18. Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 1997, 231:149-62. 10.1006/excr.1996.3457, 9056422.
19. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001, 276:40080-6. 10.1074/jbc.M105892200, 11457860.
20. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992, 24:85-95. 10.1007/BF01961241, 8095168.
21. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 1995, 34:97-117. 10.1007/BF00665783, 7647336.
22. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000, 60:5887-94.
23. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005, 65:3903-10. 10.1158/0008-5472.CAN-04-4092, 15867390.
24. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-59. 10.1210/me.15.8.1344, 11463858.
25. Su B, Wong C, Hong Y, Chen S. Growth factor signaling enhances aromatase activity of breast cancer cells via post-transcriptional mechanisms. J Steroid Biochem Mol Biol 2010,
26. Lu R, Serrero G. Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor). Proc Natl Acad Sci USA 2001, 98:142-7. 10.1073/pnas.011525198, 14558, 11134521.
27. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003, 81:600-12. 10.1007/s00109-003-0474-3, 12928786.
28. Ong CH, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell derived growth factor, acrogranin) in proliferation and tumorigenesis. Histol Histopathol 2003, 18:1275-88.
29. Serrero G. Autocrine growth factor revisited: PC-cell-derived growth factor (progranulin), a critical player in breast cancer tumorigenesis. Biochem Biophys Res Commun 2003, 308:409-13. 10.1016/S0006-291X(03)01452-9, 12914763.
30. Lu R, Serrero G. Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proc Natl Acad Sci USA 2000, 97:3993-8. 10.1073/pnas.97.8.3993, 18130, 10760271.
31. Serrero G, Ioffe O. Expression of the novel autocrine growth factor PC-Cell Derived Growth Factor in human breast cancer tissue. Human Pathology 2003, 34:1148-54. 10.1016/S0046-8177(03)00425-8, 14652816.
32. Tkaczuk KR, Yue B, Zhan M, Tait N, Yarlagadda L, Dai H, Serrero G. Increased circulating level of the survival factor GP88 (Progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast Cancer Basic and Clinical Research 2011,
33. Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 2004, 64:1737-43. 10.1158/0008-5472.CAN-03-2364, 14996734.
34. Tangkeangsirisin W, Serrero G. PC-Cell Derived Growth Factor (PCDGF/GP88) Stimulates Migration, Invasiveness and VEGF expression in Breast Cancer Cells. Carcinogenesis 2004, 25:1587-89. 10.1093/carcin/bgh171, 15117809.
35. Long BJ, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AM. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998, 67:293-304. 10.1016/S0960-0760(98)00122-8, 9883986.
36. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 2006, 66:7775-7782. 10.1158/0008-5472.CAN-05-3984, 16885381.
37. Diel P, Smolnikar K, Michna H. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of bcl-2 than tamoxifen in MCF-7 cells. Breast Cancer Res Treat 1999, 58:87-97. 10.1023/A:1006338123126, 10674872.
38. Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 2005, 95:41-8. 10.1016/j.jsbmb.2005.04.026, 15967659.
39. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 2005, 11:884s-8s.
40. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of Phosphatidylinositol-3-kinase promotes escape frpm hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010, 120:2406-13. 10.1172/JCI41680, 2898598, 20530877.
41. Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121:784-99. 10.1172/JCI43757, 3026724, 21266779.
42. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009, 69:1416-1428. 10.1158/0008-5472.CAN-08-0857, 2644349, 19190349.
43. Kim WE, Serrero G. PC cell-derived growth factor (PCDGF/GP88) stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells. Clin Cancer Res 2006, 15:4192-9.